Home > News > Latest > Aspen Faces EU Antitrust Probe Over Pricing of Cancer Drugs

Aspen Faces EU Antitrust Probe Over Pricing of Cancer Drugs

Aspen Pharmacare Holdings Ltd. faces a European Union antitrust probe for ramping up the price of cancer drugs as the EU joins a global crackdown on the soaring cost of life-saving generic medicines.

Spotlight

Other News

Dom Nicastro | April 03, 2020

More Trending news

Spotlight

Resources

Simcyp™ PBPK for Drug-Drug Interactions (DDI)

Whitepaper

Driving Down Drug Costs: How Real-Time Transparency in PBMs Can Make a Difference

Article

Association for Accessible Medicines Drug Shortages

Whitepaper

Simcyp™ PBPK for Drug-Drug Interactions (DDI)

Whitepaper

Driving Down Drug Costs: How Real-Time Transparency in PBMs Can Make a Difference

Article

Association for Accessible Medicines Drug Shortages

Whitepaper